Create Account
Log In
Dark
chart
exchange
Premium
Terminal
Screener
Stocks
Crypto
Forex
Trends
Depth
Close
Check out our API

TARA
Protara Therapeutics, Inc. Common Stock
stock NASDAQ

At Close
Oct 30, 2025 3:59:30 PM EDT
5.15USD-0.771%(-0.04)284,799
5.14Bid   5.16Ask   0.02Spread
Pre-market
Oct 29, 2025 8:32:30 AM EDT
5.09USD+0.197%(+0.01)0
After-hours
Oct 29, 2025 4:39:30 PM EDT
5.30USD+2.119%(+0.11)0
OverviewOption ChainMax PainOptionsHistoricalExchange VolumeDark Pool LevelsDark Pool PrintsExchangesShort VolumeShort Interest - DailyShort InterestBorrow Fee (CTB)Failure to Deliver (FTD)ShortsTrendsNewsNews
Jan 10, 2022
08:00AM EST  Protara Therapeutics Announces Appointment of Jathin Bandari, M.D.   GlobeNewswire Inc
Jan 4, 2022
08:00AM EST  Protara Therapeutics, Inc.(Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases with significant unmet needs, today announced that management will present at the H.C. Wainwright BioConnect Virtual Conference being held from January 10-13, 2022.   GlobeNewswire Inc
Nov 8, 2021
07:21AM EST  Oppenheimer Maintains Outperform on Protara Therapeutics, Raises Price Target to $34   Benzinga
Nov 4, 2021
08:35AM EDT  ArTara Therapeutics Q3 EPS $(0.96) Up From $(1.26) YoY   Benzinga
08:00AM EDT  Protara Therapeutics Announces Third Quarter 2021 Financial   GlobeNewswire Inc
Oct 25, 2021
04:45PM EDT  Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical stage company developing transformative therapies for the treatment of cancer and rare diseases, today announced the grants of inducement non-qualified stock options to purchase an aggregate of 44,000 shares of common stock to Mary Grendell, Protaras new General Counsel.   GlobeNewswire Inc
Oct 12, 2021
09:43AM EDT  Why Protara Therapeutics Stock Is Rising Today   Benzinga
08:13AM EDT  The Daily Biotech Pulse: NRx Stitches COVID-19 Drug Partnership, Protara Gets Nod For Starting Bladder Cancer Study, IGM Moves Beyond Oncology   Benzinga
07:25AM EDT  Protara Therapeutics Announces FDA Clearance Of IND Application For TARA-002 For Non-Muscle Invasive Bladder Cancer   RTTNews
07:21AM EDT  CORRECTION: Protara Ticker Is 'TARA'   Benzinga
07:19AM EDT  Protara Therapeutics Announces FDA Clearance Of Investigational New Drug Application For TARA-002 For Treatment Of Non-Muscle Invasive Bladder Cancer   Benzinga
07:00AM EDT  Protara Therapeutics Announces FDA Clearance of Investigational   GlobeNewswire Inc
Oct 7, 2021
08:24AM EDT  The Daily Biotech Pulse: Moderna Invests In Africa, Amgen Announces Neuroscience R&D Collaboration, Decision Day For Chemocentryx, Biophytis To Restate Results   Benzinga
Sep 17, 2021
04:05PM EDT  Protara Therapeutics, Inc.(Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases with significant unmet needs, today announced that management will present at the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit being held in a virtual setting on Wednesday, September 22, 2021 at 12:25pm ET.   GlobeNewswire Inc
Sep 13, 2021
07:00AM EDT  -Study found that approximately 30% of patients who are dependent on parenteral nutrition have cholestasis-   GlobeNewswire Inc
Sep 7, 2021
08:00AM EDT  Protara Therapeutics, Inc.(Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases with significant unmet needs, today announced that management will present at the H.C. Wainwright 23rd Annual Global Investment Conference being held virtually on September 13-15, 2021.   GlobeNewswire Inc
Aug 20, 2021
07:45AM EDT  The Daily Biotech Pulse: J&J Announces CEO Transition, FibroGen's Roxadustat Approved In Europe, GeoVax, Sorrento Announce COVID-19 Vaccine Data   Benzinga
Aug 19, 2021
10:57AM EDT  The Daily Biotech Pulse: Coherus Soars On Lung Cancer Data, Illumina Closes On Grail Buy Without Regulatory Clearance, Adagene Strikes Collaboration With Merck   Benzinga
Aug 18, 2021
09:36AM EDT  Protara Therapeutics-Sponsored Study Titled 'Prevalence of Liver Disease in Patients Dependent on Parenteral Nutrition (THRIVE-1)' Posted To ClinicalTrials.Gov Website; Study Not Yet Recruiting   Benzinga
07:38AM EDT  The Daily Biotech Pulse: AzurRx Jumps On Data, Agios' Regulatory Application For Mitapivat Accepted For Priority Review, FDA Nod For GlaxoSmithKline   Benzinga
Aug 17, 2021
08:28AM EDT  The Daily Biotech Pulse: Lilly Reorganizes Business Units In Neuroscience Focus, Helius Medical Spikes On Breakthrough Designation, Ra Medical Sells Dermatology Business   Benzinga
Aug 13, 2021
07:43AM EDT  The Daily Biotech Pulse: Moderna's Vaccine Produces Durable Response Against Variants, FDA Approves Jazz's Sleep Disorder Drug, Dermata IPO   Benzinga
Aug 10, 2021
07:55AM EDT  The Daily Biotech Pulse: Arcturus Soars On COVID-19 Vaccine Updates, Merck's Keytruda On Track For More Label Expansions, Eliem Debuts   Benzinga
Aug 5, 2021
08:23AM EDT  ArTara Therapeutics Q2 EPS $(1.14) Up From $(1.22) YoY   Benzinga
Jul 28, 2021
07:33AM EDT  The Daily Biotech Pulse: Pfizer, Bristol-Myers Squibb Earnings, Amgen Goes Shopping, GlaxoSmithKline-Vir's COVID-19 Antibody Treatment Supply Deal   Benzinga
Jul 27, 2021
11:13AM EDT  The Daily Biotech Pulse: ObsEva Surges On Out-Licensing Deal, EyeGate Appoints New CEO, 2 Positive Catalysts For Merck, Candel Therapeutics Debuts   Benzinga
Jul 20, 2021
08:20AM EDT  The Daily Biotech Pulse: Ardelyx Sinks On Regulatory Setback, AnPac Issues Positive Preannouncement, European Nod For Myovant, HCW Biologics Debuts On Wall Street   Benzinga
Jul 15, 2021
08:08AM EDT  The Daily Biotech Pulse: Galapagos Sinks On Data, J&J Recalls Sunscreen Products, FibroGen Awaits AdCom Verdict, 3 IPOs   Benzinga
Jul 8, 2021
07:45AM EDT  The Daily Biotech Pulse: Priority Review For Amgen's Asthma Treatment, Evaxion Reports Positive Skin Cancer Readout, Quidel Recalls Lyra COVID-19 Test   Benzinga
Jul 7, 2021
08:00AM EDT  Protara Therapeutics, Inc.(Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases with significant unmet needs, today announced that management will present at the Ladenburg Thalmann Healthcare Conference being held in a virtual setting on Wednesday, July 14, 2021 at 10:00am ET.   GlobeNewswire Inc
Jun 10, 2021
08:00AM EDT  Protara Therapeutics Announces Appointment of Jane Huang, M.D. to   GlobeNewswire Inc
Jun 4, 2021
10:03AM EDT  Benzinga's Top Ratings Upgrades, Downgrades For June 4, 2021   Benzinga
06:14AM EDT  HC Wainwright & Co. Initiates Coverage On Protara Therapeutics with Buy Rating, Announces Price Target of $40   Benzinga
May 14, 2021
07:59AM EDT  The Daily Biotech Pulse: CorMedix Slumps On Delay In Resubmission of DefenCath NDA, Apellis Awaits FDA Decision, Vera Therapeutics Debuts   Benzinga
May 13, 2021
08:00AM EDT  Protara Therapeutics, Inc.(Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases with significant unmet needs, today announced that management will present at two upcoming virtual investor conferences:   GlobeNewswire Inc
May 12, 2021
08:57AM EDT  The Daily Biotech Pulse: Minerva, InflaRx Report Positive Data Readouts, Lucira COVID-19 Test Kit Available On Amazon, Decision Day For Heron   Benzinga
May 11, 2021
07:54AM EDT  The Daily Biotech Pulse: FDA Authorizes Pfizer-BioNTech COVID-19 Vaccine For Adolescents, Lilly Strikes R&D Collaboration, Vaccine Stocks Novavax, Inovio Sink On Earnings   Benzinga
May 7, 2021
07:40AM EDT  The Daily Biotech Pulse: Split Verdict For Chemocentryx, NKarta-CRISPR In Cell Therapy Collaboration, Orphazyme's Clinical Trial Setback, 2 IPOs   Benzinga
May 6, 2021
08:06AM EDT  ArTara Therapeutics Q1 EPS $(1.20) Up From $(1.81) YoY   Benzinga
07:49AM EDT  The Daily Biotech Pulse: Merck's Keytruda Snags Another FDA Approval, Moderna Slips On Revenue Miss, Chemocentryx Adcom   Benzinga
07:30AM EDT  - On Track to File IND and Initiate Phase 1 Trial of TARA-002 in Patients with NMIBC by Year-End -   GlobeNewswire Inc
May 5, 2021
07:43AM EDT  The Daily Biotech Pulse: Athenex, NeoGenomics And Amryt In M&A Mix, European Nod For Roche's Cancer Immunotherapy, Earnings Deluge Continues   Benzinga
May 4, 2021
08:10AM EDT  The Daily Biotech Pulse: Vaxart Rebounds On Strong Vaccine Data, Pfizer's Beat-And-Raise Quarter, BioLineRx Data   Benzinga
Apr 30, 2021
07:31AM EDT  The Daily Biotech Pulse: Hyperphosphatemia Drug Regulatory Review Extended, Phathom Pharma Data Readout, 2 IPOs   Benzinga
Apr 29, 2021
08:15AM EDT  The Daily Biotech Pulse: Clinical Setback For Adverum, Galera Posts Data Readout, Moderna To Invest In Vaccine Manufacturing, Decision Day For Ardelyx   Benzinga
Apr 27, 2021
07:41AM EDT  The Daily Biotech Pulse: Lilly, Novartis Trail Q1 Estimates, Exec Departure At Applied Genetics, Patent Award For Scholar Rock, Aldeyra Data Readout   Benzinga
Apr 23, 2021
02:32PM EDT  Mid-Afternoon Market Update: Nasdaq Surges 1.5%; EDAP Shares Plunge   Benzinga
12:15PM EDT  Mid-Day Market Update: Skechers Jumps On Earnings Beat; Inovio Pharmaceuticals Shares Drop   Benzinga
10:22AM EDT  Mid-Morning Market Update: Markets Rise; Honeywell Beats Q1 Estimates   Benzinga
07:05AM EDT  Protara Therapeutics Says Based On FDA Feedback, Co. Intends To Complete Confirmatory, Large-Scale GMP Manufacturing Comparability In 2H And Initial Clinical Study In Pediatric Lymphatic Malformations Pending Alignment With FDA On Study Design   Benzinga
07:00AM EDT  Protara Therapeutics Provides Regulatory Update for TARA-002 for   GlobeNewswire Inc
Apr 19, 2021
04:10PM EDT  Protara Therapeutics, Inc. Reports Inducement Grants Under Nasdaq   GlobeNewswire Inc
08:00AM EDT  Protara Therapeutics Announces Appointment of Martn   GlobeNewswire Inc
Mar 11, 2021
07:34AM EST  ArTara Therapeutics Q4 EPS $(0.79) Up From $(0.96) YoY   Benzinga
07:30AM EST  - Initiation of Phase 1 Trial of TARA-002 in Patients with Non-Muscle Invasive Bladder Cancer on Track to Commence by Year-End -   GlobeNewswire Inc
Mar 10, 2021
08:00AM EST  Protara Therapeutics to Participate in the Oppenheimer 31st Annual   GlobeNewswire Inc
Mar 4, 2021
08:12AM EST  The Daily Biotech Pulse: FDA Nod For Pfizer, Kiniksa Rises On Commercialization Pact With Regeneron, Bio-Techne To Buy Diagnostic Company   Benzinga
Feb 4, 2021
08:00AM EST  Protara Therapeutics, Inc.(Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases with significant unmet needs, today announced that management will present at two upcoming virtual investor conferences:   GlobeNewswire Inc
Feb 2, 2021
08:01AM EST  Protara Therapeutics Announces Appointment of Cynthia Smith to   GlobeNewswire Inc
08:00AM EST  Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical stage company developing transformative therapies for the treatment of cancer and rare diseases with significant unmet needs, today announced the grants of inducement non-qualified stock options to purchase an aggregate of 44,500 shares of common stock to five new employees.   GlobeNewswire Inc
Dec 9, 2020
04:18PM EST  Protara Therapeutics Inc Files For Mixed Shelf Of Up To $300M   Benzinga
Dec 7, 2020
04:30PM EST  Protara Therapeutics, Inc.(Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases with significant unmet needs, today announced the promotion of Jacqueline (Jackie) Zummo, Ph.D., MPH, MBA from Senior Vice President, Research and Development Operations to Chief Scientific Operations Officer.   GlobeNewswire Inc
Dec 3, 2020
07:15AM EST  Protara Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)   RTTNews
07:00AM EST  Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical stage company developing transformative therapies for the treatment of cancer and rare diseases with significant unmet needs, today announced the grants of inducement non-qualified stock options to purchase an aggregate of 41,500 shares of common stock to two new employees.   GlobeNewswire Inc
Nov 24, 2020
07:00AM EST  Protara Therapeutics, Inc.(Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases with significant unmet needs, today announced that management will present at two upcoming virtual investor conferences in December:   GlobeNewswire Inc
Nov 12, 2020
07:29AM EST  ArTara Therapeutics Q3 EPS $(1.26) Down From $(0.92) YoY   Benzinga
07:15AM EST  -On Track to Complete GMP Batch Runs in Mid-2021 to Confirm Comparability Between TARA-002 and OK-432 --Expectto Initiate Phase 1 Trial for TARA-002 in Patients with Non-Muscle Invasive Bladder Cancerin 2021 --Requested Meeting with FDA to Discuss Path Forward for TARA-002 in Lymphatic Malformations --Strong Cash Position of$166M as of September 30, 2020 -   GlobeNewswire Inc
Nov 11, 2020
07:00AM EST  Protara Therapeutics, Inc.(Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases with significant unmet needs, today announced that its Chief Executive Officer, Jesse Shefferman, will present at the Jefferies Virtual London Healthcare Conference on Wednesday, November 18, 2020 at 1:45pm ET.   GlobeNewswire Inc
Nov 4, 2020
07:00AM EST  Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical stage company developing transformative therapies for the treatment of cancer and rare diseases with significant unmet needs, today announced the grants of inducement non-qualified stock options to purchase an aggregate of 5,200 shares of common stock to two new employees.   GlobeNewswire Inc
Oct 19, 2020
09:59AM EDT  Cowen & Co. Initiates Coverage On Protara Therapeutics with Outperform Rating, Announces Price Target of $50   Benzinga
Oct 1, 2020
05:01PM EDT  4 Sectors Moving Up In Thursday's After-Market Session   Benzinga
04:13PM EDT  Protara Therapeutics 13G Filing From Perceptive Advisors Shows New 5.8% Stake In Co.   Benzinga
Sep 23, 2020
11:13AM EDT  Insider Buys Protara Therapeutics Shares   Benzinga
Sep 22, 2020
10:45AM EDT  Shares of Protara Therapeutics, Inc. (TARA) are gaining nearly 7% on Tuesday morning after the company announced pricing of securities in concurrent public offerings of common Stock and preferred stock.   RTTNews
08:30AM EDT  Protara Therapeutics Announces Pricing Of $147.6M Of Securities In Concurrent Public Offerings Of 4.6M Shares At $16.87/Share   Benzinga
08:13AM EDT  Protara Therapeutics Announces Pricing of $147.6 Million of   GlobeNewswire Inc
Sep 21, 2020
04:02PM EDT  Protara Therapeutics Announces A Proposed Concurrent Public Offering Of Its Common Stock And Preferred Stock   Benzinga
04:01PM EDT  Protara Therapeutics Announces Proposed Concurrent Public   GlobeNewswire Inc
Sep 8, 2020
07:05AM EDT  Protara Therapeutics Provides Comparability And US Regulatory Updates For TARA-002 Supporting Advancement In Oncology And Rare Disease Indications   Benzinga
07:00AM EDT  - Company Demonstrates Initial Comparability Between TARA-002 and OK-432, Advancing to Final GMP Comparability Runs -   GlobeNewswire Inc
Sep 2, 2020
05:50PM EDT  Protara Therapeutics, Inc. (Nasdaq: TARA), a development-stage clinical biopharmaceutical company developing treatments for rare and specialty diseases with significant unmet needs, today announced the grants of inducement non-qualified stock options to purchase an aggregate of 27,500 shares of common stock to two new employees.   GlobeNewswire Inc
Aug 3, 2020
07:29AM EDT  ArTara Therapeutics Q2 EPS $(1.22)   Benzinga
07:00AM EDT  Protara Therapeutics, Inc. (Nasdaq: TARA), a development-stage company developing treatments for rare and specialty diseases with significant unmet needs, today announced financial results for the second quarter ended June 30, 2020.   GlobeNewswire Inc
Jul 29, 2020
09:38AM EDT  Benzinga's Top Upgrades, Downgrades For July 29, 2020   Benzinga
06:59AM EDT  Guggenheim Initiates Coverage On Protara Therapeutics with Buy Rating, Announces Price Target of $50   Benzinga
Jul 28, 2020
07:08AM EDT  Protara Therapeutics Receives Rare Pediatric Disease Designation For TARA-002 For The Treatment Of Lymphatic Malformations   Benzinga
07:00AM EDT  Protara Therapeutics Receives Rare Pediatric Disease Designation   GlobeNewswire Inc
Jul 24, 2020
07:09AM EDT  Protara Therapeutics Names Barry Flannelly To Board Of Directors   RTTNews
07:00AM EDT  Protara Therapeutics Announces Appointment of Barry P. Flannelly   GlobeNewswire Inc


Share
About
Pricing
Policies
Markets
API
Info
tz UTC-4
Connect with us
ChartExchange Email
ChartExchange on Discord
ChartExchange on X
ChartExchange on Reddit
ChartExchange on GitHub
ChartExchange on YouTube
© 2020 - 2025 ChartExchange LLC